Revenue grew 18% year-over-year to £11.6 million in H1 2026, with all regions contributing to growth and significant gains in the Instrumentation and Clinical segments. Cash declined to £8.9 million due to the SCD acquisition, while restructuring aims to deliver £4 million in annualized savings.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.